Maharashtra FDA has taken regulatory action against Pune-based Inducare Pharma Pvt. Ltd. after six Ayurvedic medicine samples were reported as Not of Standard Quality (NSQ), with serious quality and manufacturing deficiencies identified during inspections.
According to the FDA statement cited in the report, the action followed inspections of the manufacturing facility and findings involving microbial contamination, foreign impurities, manufacturing-record deficiencies, hygiene concerns, quality-control failures and deviations from approved formulations.
The Maharashtra FDA’s publicly available NSQ records also list multiple Inducare Pharma products against quality-test failures, including Triphala Guggul, Kanchanar Guggul, Hingvashtak Churna and Triphala Churn.
Quick Summary
Maharashtra FDA has reportedly cancelled the Ayurvedic manufacturing licence of Pune-based Inducare Pharma after six medicines were found to be Not of Standard Quality. Reported deficiencies included microbial contamination, insects and larvae, inadequate manufacturing records, hygiene issues, quality-control failures and deviations from approved formulations.
What Happened at Inducare Pharma?
The regulatory action followed inspections of the company’s manufacturing facility in Maharashtra.
According to the FDA statement provided in the report, the facility was inspected twice. The inspections reportedly identified several manufacturing and quality-control deficiencies.
These included:
- Incomplete manufacturing records
- Poor hygiene conditions
- Inadequate quality-control systems
- Manufacturing deviations
- Omission of ingredients specified in approved formulations
- Microbial contamination
- Presence of foreign impurities in some samples
The facility is associated with Inducare Pharma’s Ayurvedic manufacturing operations in Jejuri, Pune. Maharashtra FDA’s WHO-GMP-related database lists Inducare Pharmaceuticals and Research Foundation at G-32, MIDC Jejuri, Taluka Purandar, Pune.
Six Ayurvedic Medicines Reported as Not of Standard Quality
According to the FDA statement cited in the report, laboratory analysis found six medicine samples to be Not of Standard Quality (NSQ).
Medicines Mentioned in the Report
| Medicine | Reported Quality Issue |
|---|---|
| Sinhanad Guggul | Fungal growth; failed Microbial Limit Test |
| Punarnavadi Mandur | Fungal growth; failed Microbial Limit Test |
| Hingvastak Churna | Foreign impurities/quality deficiencies reported |
| Triphala Churna | Insects, larvae and other foreign impurities reported |
| Triphala Guggul | Microbial limits exceeded |
| Kanchanar Guggul | Microbial limits exceeded |
NSQ means that a drug sample does not comply with one or more prescribed quality specifications.
The Maharashtra FDA’s NSQ database independently lists Inducare Pharma products against quality failures, including Triphala Guggul and Kanchanar Guggul for Microbial Limit Test issues, while Hingvashtak Churna and Triphala Churn also appear in the database with specified quality-test deficiencies.
Fungal Contamination Reported in Two Medicines
The report states that samples of Sinhanad Guggul and Punarnavadi Mandur showed fungal growth and failed the Microbial Limit Test.
Microbial quality testing is particularly important for medicines because unacceptable microbial contamination can indicate problems with raw materials, manufacturing conditions, environmental controls, handling or storage.
The reported findings therefore raise concerns about the effectiveness of quality-control and manufacturing practices at the facility.
Insects and Larvae Found in Some Samples
The report also states that Hingvastak Churna and Triphala Churna samples contained insects, larvae and other foreign impurities.
The Maharashtra FDA’s NSQ records include Hingvashtak Churna and Triphala Churn manufactured by Inducare Pharma’s Jejuri facility.
Such findings are significant because finished pharmaceutical and Ayurvedic products are expected to meet prescribed quality and purity specifications.
Triphala Guggul and Kanchanar Guggul Exceeded Microbial Limits
The report further states that samples of:
- Triphala Guggul
- Kanchanar Guggul
exceeded prescribed microbial limits.
The Maharashtra FDA’s NSQ listing also records these two Inducare Pharma products under Microbial Limit Test failures.
GMP Violations Reported by Maharashtra FDA
The inspections reportedly identified several deficiencies related to Good Manufacturing Practices (GMP).
The reported issues included:
1. Incomplete Manufacturing Records
Manufacturing records are important for documenting how a batch was produced, tested and released.
2. Poor Hygiene
Adequate hygiene and sanitation are fundamental components of pharmaceutical manufacturing.
3. Inadequate Quality-Control Systems
Quality-control systems help ensure that raw materials, in-process materials and finished products meet established specifications.
4. Deviation From Approved Formulations
The report states that certain approved ingredients were omitted during actual manufacturing.
This is particularly significant because the composition of an approved formulation is part of the product’s defined quality requirements.
Why Are GMP Standards Important?
Good Manufacturing Practices (GMP) are designed to help ensure that medicines are consistently produced and controlled according to appropriate quality standards.
GMP covers areas such as:
- Personnel hygiene
- Manufacturing facilities
- Equipment
- Raw-material control
- Documentation
- Production processes
- Quality control
- Testing
- Storage
- Batch records
Failures in these areas can potentially affect the identity, strength, quality or purity of pharmaceutical products.
Maharashtra FDA’s Regulatory Action
According to the FDA statement cited in the report, the manufacturing licence was permanently cancelled following the inspections and quality findings.
The reported action was taken under the regulatory framework governing drug manufacturing, including provisions of the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and applicable GMP requirements.
FDA’s Message on Drug Quality
The FDA statement quoted in the report emphasised that ensuring safe, quality and effective medicines is a key responsibility of the regulator and that manufacturers are required to comply with applicable drug laws and GMP standards.
The reported action demonstrates the regulator’s role in taking enforcement measures when serious manufacturing or quality deficiencies are identified.
What Does “Not of Standard Quality” Mean?
A medicine classified as Not of Standard Quality (NSQ) means that the tested sample does not meet one or more prescribed standards or specifications.
An NSQ finding can relate to different parameters, including:
- Assay
- Dissolution
- Microbial limits
- Sterility
- Description
- Identification
- Physical characteristics
- Content uniformity
- Other specified quality requirements
NSQ does not automatically mean that every batch of a company’s products has failed. It refers to the specific sample/batch identified in the regulatory testing.
Why Is This Action Important for the Pharma Industry?
The case highlights the importance of maintaining robust quality systems throughout pharmaceutical and Ayurvedic manufacturing.
For manufacturers, the incident reinforces the need for:
- Proper documentation
- Validated manufacturing processes
- Effective QC testing
- GMP compliance
- Proper environmental controls
- Raw-material quality checks
- Correct formulation practices
- Batch traceability
For pharmacists and healthcare professionals, regulatory quality alerts can provide important information when evaluating medicine quality and supply.
What Should Patients and Pharmacists Know?
Patients should not panic based solely on a news report about a company’s regulatory action.
An NSQ finding generally relates to the specific sample or batch identified by the regulator. Patients who have concerns about a particular product should check the product name, manufacturer and batch details and consult a qualified healthcare professional or pharmacist.
Pharmacists and distributors should follow applicable regulatory instructions regarding any affected batch or product.
What Does This Mean for Pharmacy Students?
This case is also relevant for B.Pharm, D.Pharm and M.Pharm students because it demonstrates the practical importance of subjects such as:
- Pharmaceutical Quality Assurance
- GMP
- Quality Control
- Pharmaceutical Jurisprudence
- Microbiology
- Drug regulatory affairs
- Manufacturing documentation
It is a real-world example of how manufacturing deficiencies can lead to regulatory enforcement.
Key Takeaways
- Maharashtra FDA has reportedly taken major regulatory action against Inducare Pharma Pvt. Ltd.
- The action followed inspections of the company’s Ayurvedic manufacturing facility.
- Six medicine samples were reported as Not of Standard Quality (NSQ).
- Sinhanad Guggul and Punarnavadi Mandur were reported to have fungal growth.
- Hingvastak Churna and Triphala Churna were reported to contain insects, larvae and other foreign impurities.
- Triphala Guggul and Kanchanar Guggul were reported to have exceeded prescribed microbial limits.
- The inspection reportedly identified documentation, hygiene, quality-control and formulation-related deficiencies.
- Maharashtra FDA’s public NSQ records independently list several Inducare products against quality-test failures.
- The case highlights the importance of GMP compliance and pharmaceutical quality assurance.
Frequently Asked Questions
1. Why did Maharashtra FDA take action against Inducare Pharma?
According to the FDA statement cited in the report, the action followed inspections that identified serious quality, manufacturing, documentation, hygiene and GMP-related deficiencies.
2. How many Inducare Pharma medicines were reported as NSQ?
The report states that six medicine samples were found to be Not of Standard Quality.
3. Which Inducare medicines were reported to have fungal contamination?
According to the report, Sinhanad Guggul and Punarnavadi Mandur showed fungal growth and failed the Microbial Limit Test.
4. Which medicines were reported to contain insects and larvae?
The report states that Hingvastak Churna and Triphala Churna contained insects, larvae and other foreign impurities.
5. What happened with Triphala Guggul and Kanchanar Guggul?
According to the report, both samples exceeded prescribed microbial limits. Maharashtra FDA’s NSQ database also lists these products against Microbial Limit Test failures.
6. What does NSQ mean in pharmaceuticals?
NSQ means Not of Standard Quality. It indicates that a tested drug sample did not comply with one or more prescribed quality specifications.
7. What GMP violations were reported?
The reported deficiencies included incomplete manufacturing records, poor hygiene, inadequate quality-control systems and deviations from approved formulations.
8. Does an NSQ alert mean every batch of the medicine is unsafe?
Not necessarily. An NSQ finding generally relates to the specific sample or batch tested by the regulator. The applicable regulatory instructions should be followed for the affected product or batch.
Conclusion
The reported action against Inducare Pharma highlights the critical role of quality assurance, GMP compliance and regulatory oversight in Ayurvedic and pharmaceutical manufacturing.
The identification of NSQ samples, microbial-limit failures and reported foreign impurities demonstrates why manufacturers must maintain effective quality-control systems, accurate documentation and strict adherence to approved formulations.
For pharmacy students and professionals, the case is a practical example of how GMP, pharmaceutical quality assurance and drug regulatory requirements operate beyond textbooks.
GDC Classes will continue to cover important pharmaceutical regulatory, quality-control and industry updates for pharmacy students and professionals.
Recommended Products
